Breaking news

The objective of this retrospective cohort study was to compare the rate of ischaemic stroke between patients with COVID-19 and patients with influenza, a respiratory viral illness previously associated with stroke.

The objective of this prospective, open-label, randomised clinical trial, was to evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalised with COVID-19.

The objective of this case-series study, recently published in JAMA Neurology, was to report the neurological manifestations of children with COVID-19 who presented with SARS-CoV-2 infection and neurological symptoms to Great Ormond Street Hospital for Children (London, UK) between March 1, 2020, and May 8, 2020.

The objective of this multicentre cohort study, recently published in JAMA Internal Medicine, was to assess factors associated with death and to examine inter-hospital variation in treatment and outcomes for patients with COVID-19.

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

In this study recently published in the New England Journal of Medicine, the authors conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with candidate vaccine mRNA-1273 (which encodes the stabilised prefusion SARS-CoV-2 spike protein) in a dose of 25 μg, 100 μg, or 250 μg.

In this controlled, open-label trial recently published in the New England Journal of Medicine, the authors randomly assigned patients who were hospitalised with COVID-19 to receive either oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or usual care.

Members of the EAN Scientific Panel on Infectious Diseases have recently published a systematic review of neurological manifestations of SARS‐CoV‐2 infection in the European Journal of Neurology.

In this paper, just published in the New England Journal of Medicine, the authors report neuropathological findings from autopsies of 18 consecutive patients with SARS-CoV-2 infection who died in a single teaching hospital between April 14 and April 29, 2020.

This retrospective multicentre study aimed to assess the number of patients with acute ischaemic cerebrovascular events seeking inpatient medical emergency care since the implementation of social distancing measures during the COVID-19 pandemic.

In this paper recently published in Neurology, the authors aimed to determine whether neurological manifestations are common in hospitalised COVID-19 patients and to describe their main characteristics.

In this study, recently published in Neurology Neuroimmunology & Neuroinflammation, the authors conducted a survey on the risk of COVID-19 in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).

In this paper, the authors report a case of Guillain-Barré syndrome (GBS) with onset 2 weeks after SARS-CoV-2 infection and highly elevated serum antibodies against SARS-CoV-2, supporting an association between SARS-CoV-2 disease and GBS.

In this prospective observational cohort study with rapid data gathering and near real-time analysis, the authors characterised the clinical features of patients admitted to hospital with Covid-19 in the United Kingdom during the growth phase of the first wave of the outbreak. Patients were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organisation (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and risk factors associated with mortality in hospital were explored.

Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In the present COVID-19 pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients.